Lumipulse^® G ADxPLORER^® β-Synuclein

Recent data suggest that the presynaptic brain-specific protein β-synuclein is a promising biomarker of synaptopathy in both cerebrospinal fluid (CSF) and blood^1,2,3. Previously established immunoassays have been described using α/β-synuclein antibodies. However, due to the high abundance of α-synuclein in blood, β-synuclein-specific antibodies are needed to minimize cross-reactivity. The clinical utility of β-synuclein, however, remains to be further established.

The Lumipulse® G ADxPLORER® β-Synuclein assay was developed using two proprietary monoclonal antibodies. The ADx416 mAb (90588) serves as the capture antibody, combined with an alkaline phosphatase-conjugated Fab fragment derived from the ADx415 mAb (90587), which specifically targets the unique β-synuclein region. The assay is calibrated with the full-length recombinant β-synuclein protein.
 

References:

1. Halbgebauer et al. Blood B-Synuclein and Neurofilament Light Chain During the Course of Prion Disease. Neurology. 2022 Apr 5;98(14):e1434-e1445.
2. Oeckl et al. Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. J Proteome Res. 2020 Mar 6;19(3):1310-1318.
3. Halbgebauer et al. Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2021 Apr;92(4):349-356.

 
Lumipulse is a registered trademark of Fujirebio Inc.
ADxPLORER is a registered trademark of Fujirebio Europe NV.